echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Over 100 million US dollars! Hausen and EQRx reach a cooperation agreement for Amitinib outside China

    Over 100 million US dollars! Hausen and EQRx reach a cooperation agreement for Amitinib outside China

    • Last Update: 2020-07-31
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Guide: Amitinib, a third-generation EGF-TKI inhibitor developed by Howson Pharmaceuticals, was approved for sale in China in March.
    today, Hansen Pharmaceuticals announced that Henson (Shanghai) Health Technologies and Howson Pharmaceuticals have entered into strategic partnerships and license agreements with EQRx to grant EQRx exclusive licenses to develop, produce and commercialize the third generation of EGFR-TKI Amitini (and any products contained in or made up of amatinib) in the therapeutic areas of cancer, cancer-related and inflammatory diseases.
    Amitinib, a third-generation EGFR (epidermal growth factor receptor) -TKI (tyrosine kinase inhibitor) developed by Haussen Pharmaceuticals, was approved in China in March this year for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have previously been treated with EGFR-TKI and are positive in the T790M mutation.
    under the license agreement, Henson (Shanghai) Health Technologies and Howson Pharmaceuticals are entitled to receive down payments and registration and development milestone payments of approximately $100 million (excluding other potential commercial milestone payments and tiered royalties based on net sales).
    the milestone payment must be made only if the milestone is reached and paid in the first time the milestone event has occurred.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.